Antiplatelet therapy in peripheral arterial disease. Consensus statement - ScienceDirect
Antiplatelet therapy in peripheral arterial disease. Consensus statement - ScienceDirect
Doses of antiplatelet co-therapies | Download Table
ANTIPLATELET AGENTS AND ASPIRIN FOR PREVENTION
Figure 13 from Antiplatelet effect of aspirin in patients with coronary artery disease. | Semantic Scholar
Dose- and time-dependent antiplatelet effects of aspirin Christina Perneby, N. Håkan Wallén, Cathy Rooney, Desmond Fitzgerald, Paul Hjemdahl Published. - ppt download
Treating Patients on Antiplatelet Therapy
Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs | PNAS
Aspirin as an Antiplatelet Drug | NEJM
Antiplatelet Therapy | Thoracic Key
Dual Antiplatelet Therapy for High-Risk TIA and Minor Stroke: BMJ Rapid Recommendation | AAFP
Dose- and time-dependent antiplatelet effects of aspirin Christina Perneby, N. Håkan Wallén, Cathy Rooney, Desmond Fitzgerald, Paul Hjemdahl Published. - ppt download
European Guidelines for Aspirin | The Aspirin Foundation
Aspirin and an oral anticoagulant – can they be used together? - NPS MedicineWise
Antiplatelet Drugs
Antiplatelet Therapy in Acute Coronary Syndrome | ECR Journal
Frontiers | Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Antiplatelet Drugs | Concise Medical Knowledge
Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials | Stroke
Aspirin antiplatelet effects are associated with body weight - ScienceDirect
Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy | tctmd.com
The art of delivering evidence-based dual antiplatelet therapy. | Semantic Scholar
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial - The Lancet
JCM | Free Full-Text | Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls
Frontiers | Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
